Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Desipramine can predict a clinical response in bowel disorders

Blood levels of Desipramine are associated with a clinical response in functional bowel disorders, however, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response, reports the latest issue of American Journal of Gastroenterology

News image

fiogf49gjkf04

As shown in the per protocol analysis of a recent randomized, controlled trial, when tolerated, Desipramine is effective over placebo in treating moderate-to-severe functional bowel disorders.

Clinical experience suggests that the benefit from tricyclic antidepressants in functional bowel disorders can be achieved at doses lower than those used to treat major depression.

Within psychiatry, when using higher dosage of tricyclic antidepressants, plasma levels can be used to adjust daily dosage to optimize a treatment response.

However, in functional bowel disorders, it is not known whether plasma levels at the lower dosage are similarly related to a clinical response.

Dr Halpert and colleagues from Canada determined whether Desipramine blood levels or dose taken can predict a clinical response in treating functional bowel disorders.

The researchers included 431 patients with functional bowel disorder that were part of a study of 12 weeks of antidepressant and psychological treatment at the University of North Carolina and the University of Toronto.

There was a modest correlation between mean Desipramine dose and Desipramine blood level at week 6
American Journal of Gastroenterology

The research team studied those participants who completed treatment (per protocol analysis) taking Desipramine (N = 97, dose 50,150 mg/day) or pill placebo (N = 5,513 pills/day).

The primary outcome measure was defined by the investigators as a composite score (Satisfaction with Treatment, McGill Pain Questionnaire, Global Well-being, and Irritable Bowel Syndrome-Quality of Life).

The composite score was correlated with Desipramine plasma levels at week 6, and the number of pills taken over the duration of the 12 week treatment period.

In addition, the reasearchers also compared Desipramine dose with Desipramine plasma levels.

The team reported a modest correlation between mean Desipramine dose at weeks 5 and 6 and Desipramine blood level at week 6.

However, the research team noted no significant correlations between the composite score either with Desipramine dose or with Desipramine blood levels.

Dr Halpert concludes, “Detectible blood levels of Desipramine are associated with a clinical response in functional bowel disorders.”

“However, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response."

American Journal of Gastroenterology 2005: 100(3): 664
14 March 2005

Go to top of page Email this page Email this page to a colleague

 19 February 2018 
The effectiveness of screening colonoscopy in the right colon was not significantly different from that in the left colon/rectum
 19 February 2018 
No significant differences, among racial or ethnic groups, found in patients with significant fibrosis
 19 February 2018 
Hydrogen production greater in patients on a fructan-containing diet, than those following a maltodextrin-containing diet

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us